



2007-05-29

Pressrelease

Status – listing of Oasmia

Oasmia Pharmaceutical AB has previously informed that the company has applied for a listing.

The company will be listed on the NGM Stock Exchange (Equity Regulated Market) and the listing is planned for 14th of September 2007.

The purpose of the listing is to simplify trade in the company's shares, primarily for institutional and international investors, and to improve pre-requisites in the strong and expansive development that the company is currently in. Listing prospectus and other information will be published latest on the first day of trading.

Oasmia Pharmaceutical is a pharmaceutical company that specialises in the treatment of severe diseases. Oasmia develops pharmaceuticals for the future.

A pharmaceutical company based on the latest concepts in bio-organic chemistry. The main idea is to improve the treatment of serious diseases. Primarily, this development is in oncology and treatment with cytostatics but Oasmia also conducts research in antibiotics, asthma and neurological diseases. Oasmia has in-house production capacity of pharmaceuticals for clinical trials, both company related and others. Oasmia has developed several products based on existing pharmaceuticals in a new environment, which leads to whole new solutions for cancer treatment. These products give Oasmia a solid product portfolio within oncology with several products in clinical or pre-clinical phase.

Oasmia is noted on NGM Nordic MTF.

More information is available at www.ngm.se or www.oasmia.com.

For further information contact info@oasmia.com or call +46 18 50 54 40.